KETAKI VAIDHYANATHAN: Open Payments
NPI 1992904445 · MONTCLAIR, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,421 in 89 payments from 11 companies in 2025. Trend: 2023 $436 · 2024 $622 · 2025 $1,421
Food & beverage: $1,316Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $310 |
| Alkermes, Inc. | 11 | $210 |
| Otsuka America Pharmaceutical, Inc. | 14 | $199 |
| Janssen Pharmaceuticals, Inc | 18 | $164 |
| Lundbeck LLC | 9 | $160 |
| E.R. Squibb & Sons, L.L.C. | 9 | $155 |
| Neurocrine BioSciences, Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Validus Pharmaceuticals LLC | 1 | $14 |
Products named: ABILIFY ASIMTUFII, ARISTADA, INVEGA SUSTENNA, COBENFY, AUSTEDO XR, INGREZZA, UZEDY, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
